Temodar (Temozolomide)

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Diakonos Oncology Corporation

Conditions

Glioblastoma (GBM)Glioblastoma MultiformeMelanoma

Phase 1

Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM

TerminatedNCT00508456

M.D. Anderson Cancer CenterGlioblastoma Multiforme

Start: 2004-08-31End: 2008-11-30Updated: 2012-01-16

A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma

TerminatedNCT01067066

M.D. Anderson Cancer CenterMelanoma

Start: 2010-02-03End: 2016-07-06Updated: 2017-07-21

Phase 2

DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

RecruitingNCT06805305

Diakonos Oncology CorporationGlioblastoma (GBM)

Start: 2025-03-17End: 2032-03-01Target: 180Updated: 2026-03-24

Related Papers

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma

medRxiv2026-04-02